• Net loss narrowed 2.25% to $8.7 million.
• R&D expenses jumped 69.23% to $4.4 million on higher drug manufacturing, NSCLC data management, Plinabulin combination research, regulatory consulting, and personnel costs.
• G&A expenses fell 24.59% to $4.6 million on lower personnel costs, reduced consulting expenses, and lower corporate overhead.
• Cash, cash equivalents, and short-term investments totaled $12.6 million.
• Chief Executive Officer Lan Huang said the company remained focused on advancing the DUBLIN-4 confirmatory trial for Plinabulin in EGFR wild-type non-squamous NSCLC post immune checkpoint inhibitors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-001890), on March 25, 2026, and is solely responsible for the information contained therein.